BPDCN; relapsed/refractory T-cell acute lymphoblastic leukemia

Clinical trials for BPDCN; relapsed/refractory T-cell acute lymphoblastic leukemia explained in plain language.

Never miss a new study

Get alerted when new BPDCN; relapsed/refractory T-cell acute lymphoblastic leukemia trials appear

Sign up with your email to follow new studies for BPDCN; relapsed/refractory T-cell acute lymphoblastic leukemia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse

Disease control Recruiting now

This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…

Matched conditions: BPDCN; RELAPSED/REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control

Last updated Jun 27, 2026 12:06 UTC

BPDCN; relapsed/refractory T-cell acute lymphoblastic leukemia

Get alerted when new BPDCN; relapsed/refractory T-cell acute lymphoblastic leukemia trials appear

Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse